Lilly stock climbs on positive arthritis drug test
A potential rheumatoid arthritis treatment from drugmakers Eli Lilly and Co. and Incyte Corp. fared better than another drug in late-stage testing, Lilly said Tuesday.
Health Care Businesses
Articles
Settlement clears way for Lilly to launch once-a-day insulin
The settlement with France-based Sanofi SA clears up uncertainty over a drug that could rack up more than $1 billion in sales by 2020, according to Wall Street analysts.
Applications to Marian medical school keep rising
With the number of applications to Marian’s College of Osteopathic Medicine running twice as high as initially expected, school leaders say they are confident Marian can help reduce a looming physician shortage in Indiana.
Lilly’s heart study sets up showdown with Novo’s Victoza
Unprecedented results from a cardiovascular study on a diabetes medicine sold by Eli Lilly and Co. turns up the pressure on rival Novo Nordisk, which will release data from a similar study on its competing drug next year.
Group urges Dems to tackle pharmaceutical prices
Pharmaceutical industry members are likely to dislike the proposal, which would require them disclose how much they spend on research and development, production, and sales and marketing.
Jardiance study lifts Lilly shares to 15-year high
Eli Lilly shares soared Thursday after study results showed Jardiance sharply reduced chances of dying in diabetic patients at high risk of heart complications. The study prompted at least one analyst to predict the drug could bring in billions of dollars by the end of the decade.
Lilly shares jump on latest data from diabetes drug
A diabetes pill called Jardiance sold by Eli Lilly and Co. cut deaths from heart attacks and strokes in thousands of patients, the first drug to show promise in helping subdue two of the world’s most rampant health epidemics.
Senior health care firm operator Trilogy sold in $1.2B deal
Trilogy Health Services LLC, which operates more than 70 senior-living facilities in Indiana, is being acquired. The company has at least 14 properties in central Indiana, including two in Indianapolis.
Drug-price increases slow as benefits managers get tough
A new analysis shows attempts by drugmakers to raise prices are being wiped out in negotiations with managers of drug insurance benefits like Express Scripts Holding Co. and CVS Health Corp.
More precise medical codes aim to track quality of care
On Oct. 1, the nation’s physicians and hospitals must start using a massive new coding system to describe your visit on insurance claims so they get paid.
Experimental osteoporosis drug bests Lilly’s Forteo in study
The experimental medicine, called romosozumab, showed better results than Eli Lilly and Co.’s Forteo after 12 months, Amgen and UCB said in a joint statement Wednesday.
Lilly wins patent ruling over blockbuster drug Alimta
Eli Lilly and Co. won a court ruling that will keep generic versions of the chemotherapy drug Alimta off the U.S. market until a patent expires in 2022.
Lilly shares jump after positive study of diabetes drug
Lilly’s stock had its biggest intraday gain since 2009 Thursday after it announced trial results that showed Jardiance lowered the risk of heart attacks, stroke and death in a large trial of adults with type 2 diabetes.
Indy medical device firm plans 125-job expansion
Catheter Research Inc.—which makes single-use medical devices, such as catheters—plans a $4.8 million expansion that will relocate its headquarters to larger space on the northwest side.
Lilly accused at trial of hiding Cymbalta ‘brain zap’ risk
The drugmaker faces as many as 5,000 cases claiming it downplayed Cymbalta’s withdrawal risks, which allegedly include electrical-shock sensations, vomiting and insomnia.
Health insurer deal fever may spread to hospitals next
Seeing mergers like Anthem’s planned acquisition of Cigna Corp., hospitals could decide that striking deals of their own could improve their negotiating power over medical reimbursements.
Lilly posts lackluster profit but boosts full-year forecast
Eli Lilly and Co.’s profits plunged 18 percent in the second-quarter but still easily beat the lowered expectations of Wall Street analysts.
Alzheimer’s trials offer little certainty for investors, patients
Shares of Eli Lilly and Co. stagnated in Wednesday morning trading as investors and patients wished that the effects of solanezumab were more pronounced. Rival Biogen offered muddy results from its own Alzheimer’s drug.
Study shows Lilly’s Alzheimer’s drug has small but lasting benefit
New data released Wednesday morning suggest that Eli Lilly and Co.’s Alzheimer’s drug has a modest but lasting impact on the memory-sapping disease. But analysts worry the impact is too small to be meaningful.
Indy-based health data firm snares $1.5M in VC round
Healthiest Employers LLC, which collects and measures corporate health information, plans to use the funds to drive sales of its analytics software.